Clémence Denis Beslin’s Post

Today, our board member Elena Moya delivered a presentation on why health systems must deliver with patients at Pharma 2024, organised by Reuters Events in Barcelona. During her presentation, she showcased why patient involvement is non-negotiable when it comes to the success of our healthcare systems. Before diving into technical solutions to strengthen the involvement of the patient community, she emphasised the importance of understanding why patient involvement is so crucial and how it adds value to healthcare systems. Patients' practical understanding of healthcare systems is essential in developing services that align with their needs. To make this possible, we need to promote a cultural shift in how we interact with patients. #PatientPerspective

Meet senior experts from Avalere Health at #isporeurope 2023, at booth C3-065. Find out how our best-in-class, policy, access, value, and evidence services are supporting leading life sciences companies, health plan providers, and investors.   Sign up for Avalere Health insight sessions on the following topics:  1. Harnessing the power of real-world evidence to elevate value 2. Joint clinical assessments (JCAs): navigating the complexities in 2025 3. Early pipeline planning: tools and best practices for early decision-making   We will also be running demonstrations of our suite of unique digital applications: 1. hēRo3: Advanced HEOR modelling simplified 2. PRMA Healthcheck®: Maximize the value of your asset portfolio 3. PRMA Navigator®: Market access operational excellence, delivering high-quality multiple HTA and other payer submissions 4. PRMA Tracker®: Monitor the evolving HTA and P&R landscape for competitors or products of interest   Reserve your spot today https://lnkd.in/gK5-zJrQ #ISPOREurope #WeAreAvalereHealth

As we put DIA 2024 in the rearview window, Alira Health is energized by the insights and open-minded discussions that Clients are willing to have, to learn more about everything from Clinical Trial Strategies advancements to how our Alira Health Digital Platform is advancing everything from simple RWE inquiries to Registries to Hybrid/DCTs. Have you listened to any 3rd party insights - for your very expensive clinical development plans?

I really enjoyed talking about digital health and partnerships on Thursday with Julia Henkels John Drakenberg Kimberley Ferguson Marissa "Missy" Pittard at the DTx Conference Series in Los Angeles, CA. Some key takeaways for the community from the great discussion are: 1. Identify partners that share the same mission and vision as your company, your team and your product/service. At OMRON Healthcare, Inc. that's going for zero, eliminating heart attacks and strokes. 2. Find champions and internal stakeholders that will advocate for a joint future vision and state. This will help build momentum and keep momentum during the long process from ideation -> development -> market launch. 3. Clearly define the joint partnership ROI and business model by understanding your partners key needs (e.g., reducing CAC) vs. just presenting YOUR solution, roadmap, needs, etc. 4. Look for partnerships where you can combine strengths to make measurable strides towards your company mission. Our partnership with AliveCor is a good example of how we applied these criteria, and its made a difference. What did we miss that's been learned in the past few years of digital health partnerships and therapeutics that can be applied moving forward?

Just returned from DIA Europe 2024, where "Collaborating for Healthcare Innovation" was the conference theme. This event was a great reminder of the importance of working together to achieve great things. - We must collaborate, across industry and with regulators as we share a common goal 'Making effective and safe medicines accessible to those how need it'. Rather than seeing each other as adversaries, collaboration, open dialogue, and problem-solving should be our guiding principles. Together, we can drive positive change in the healthcare landscape. I came back from the conference with new knowledge, ideas, and loads of notes. Now, it's time to think about how I can apply these insights to benefit my work going forward. #diaeurope2024 #regulatoryaffairs #regulatoryscience

I Just watched the insightful debate about the future role of health in Europe. A radical change toward further collaboration, more integration, coordination, and harmonization, targeted funds, supportive legislation, and initiatives for the innovative life science industry should be followed to improve the supply chain, affordability, and access to treatment solutions. Tackling disease through EU action plans might be vital, as emphasized by panelists, however, I would like to highlight the role of enhancing the regulatory framework to improve access to health innovative treatments, as a lesson learned after the pandemic. This could make product development more agile, secure an efficient and robust drug supply across Europe, and leverage fair patient access through a more resilient and harmonized system.

The world of #digitalhealth is on full display during the inaugural HLTH Europe conference in #Amsterdam this week. It is so fascinating to see all of the ideas and excitement, spanning all the changemakers that are trying to challenge how we approach healthcare. Many thanks for our BD&L team that’s representing us! Stop by booth C40 to see the team and our Bayer | Consumer Health colleagues. #teambayer #healthforall #digitalhealth #HLTHEurope #HLTHEurope2024

We are excited to introduce FutureMeds’ Promis of Progress: The Progress P.A.C.T. Built on 4 pillars: People, Access, Collaboration, and Truth, it is our company promise and guiding philosophy, designed to shape our interactions with patients, clients, partners, and our team. “𝙐𝙣𝙞𝙛𝙮𝙞𝙣𝙜 𝙨𝙞𝙩𝙚 𝙩𝙚𝙖𝙢𝙨 𝙖𝙘𝙧𝙤𝙨𝙨 𝙢𝙪𝙡𝙩𝙞𝙥𝙡𝙚 𝙘𝙤𝙪𝙣𝙩𝙧𝙞𝙚𝙨 𝙪𝙣𝙙𝙚𝙧 𝙤𝙣𝙚 𝙥𝙪𝙧𝙥𝙤𝙨𝙚 𝙝𝙖𝙨 𝙗𝙚𝙚𝙣 𝙖 𝙛𝙤𝙧𝙢𝙞𝙙𝙖𝙗𝙡𝙚 𝙩𝙖𝙨𝙠. 𝙒𝙚’𝙫𝙚 𝙨𝙥𝙚𝙣𝙩 𝙤𝙫𝙚𝙧 𝙩𝙬𝙤 𝙮𝙚𝙖𝙧𝙨 𝙘𝙧𝙚𝙖𝙩𝙞𝙣𝙜 𝙖 𝙫𝙖𝙡𝙪𝙚 𝙨𝙮𝙨𝙩𝙚𝙢 𝙩𝙝𝙖𝙩 𝙖𝙡𝙞𝙜𝙣𝙨 𝙥𝙚𝙧𝙛𝙚𝙘𝙩𝙡𝙮 𝙬𝙞𝙩𝙝 𝙤𝙪𝙧 𝙢𝙞𝙨𝙨𝙞𝙤𝙣 𝙤𝙛 𝙙𝙚𝙡𝙞𝙫𝙚𝙧𝙞𝙣𝙜 𝙛𝙪𝙩𝙪𝙧𝙚 𝙢𝙚𝙙𝙞𝙘𝙞𝙣𝙚𝙨 𝙩𝙤 𝙥𝙖𝙩𝙞𝙚𝙣𝙩𝙨,” added Radoslaw (Radek) Janiak, CEO 𝗣𝗲𝗼𝗽𝗹𝗲 𝗺𝗮𝗸𝗲 𝗽𝗿𝗼𝗴𝗿𝗲𝘀𝘀 Clinical research depends on the dedication, commitment & compassion of people. 𝗔𝗰𝗰𝗲𝘀𝘀 𝗯𝗲𝗻𝗲𝗳𝗶𝘁𝘀 𝗮𝗹𝗹 We believe everyone deserves the opportunity to thrive. 𝗖𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻 𝗰𝗼𝗻𝗻𝗲𝗰𝘁𝘀 Great things come from working together. 𝗧𝗿𝘂𝘁𝗵 𝗯𝘂𝗶𝗹𝗱𝘀 𝘁𝗿𝘂𝘀𝘁 We are committed to fostering an environment that promotes honesty. “𝙄 𝙝𝙖𝙫𝙚 𝙛𝙪𝙡𝙡 𝙘𝙤𝙣𝙛𝙞𝙙𝙚𝙣𝙘𝙚 𝙩𝙝𝙖𝙩 𝙬𝙞𝙩𝙝 𝙩𝙝𝙚 𝙋𝙧𝙤𝙜𝙧𝙚𝙨𝙨 𝙋.𝘼.𝘾.𝙏. 𝙖𝙣𝙙 𝙤𝙪𝙧 𝙩𝙚𝙖𝙢𝙨’ 𝙨𝙪𝙥𝙥𝙤𝙧𝙩, 𝙬𝙚 𝙬𝙞𝙡𝙡 𝙘𝙪𝙡𝙩𝙞𝙫𝙖𝙩𝙚 𝙖 𝙘𝙤𝙢𝙥𝙖𝙣𝙮 𝙘𝙪𝙡𝙩𝙪𝙧𝙚 𝙖𝙩 𝙁𝙪𝙩𝙪𝙧𝙚𝙈𝙚𝙙𝙨 𝙩𝙝𝙖𝙩 𝙘𝙖𝙣 𝙮𝙞𝙚𝙡𝙙 𝙨𝙞𝙜𝙣𝙞𝙛𝙞𝙘𝙖𝙣𝙩 𝙡𝙤𝙣𝙜-𝙩𝙚𝙧𝙢 𝙗𝙚𝙣𝙚𝙛𝙞𝙩𝙨 𝙛𝙤𝙧 𝙥𝙖𝙩𝙞𝙚𝙣𝙩𝙨, 𝙥𝙖𝙧𝙩𝙣𝙚𝙧𝙨 𝙖𝙣𝙙 𝙤𝙪𝙧 𝙩𝙚𝙖𝙢,” said Wojciech Szczepanik, Executive VP of Operations #ClinicalTrials #ClinicalResearch

This week, our COO, Kate Woolland, joined IQVIA UK and Ireland , together with a panel of experts, to discuss how to overcome the challenges hindering the adoption of accelerated innovation in the healthcare and life science industry, for the latest installment of "Making Market Access Real".   The main topic of discussion revolved around the unsustainability of healthcare in its current form. Challenges in funding, productivity, workforce shortages, and the backlog in the post-pandemic era, along with health equity and access issues, create significant obstacles. Innovation plays a fundamental part in tackling these challenges. However, it is not the innovation itself but the adoption of innovation that presents the biggest challenge for the industry.   💡 At Closed Loop Medicine, our aim is to provide a pathway for all individuals to access high-quality personalized treatment, addressing the current shortfall in scalable personalized healthcare solutions, by enabling real-time, real-world drug dose optimization of both new and established medicines – offering precision care for all while supporting healthcare providers.   If you haven’t already, watch the video to join the conversation on what’s happening to drive innovation forward. 👇   #Healthcare #Innovation #NHS #PrecisionCare 

There is nothing more enjoyable in business than watching teams willingly engage in all activities aimed at strengthening the culture in the organization.